Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415039 | 1.00 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BFYNPTPN1 | |
| SCHEMBL2412788 | 0.86 | TUBB4A (0.32) | ADRA1DADRA1AADRA1BPTPN1PTPN6 | |
| SCHEMBL2412786 | 0.86 | TUBB4A (0.32) | ADRA1DADRA1AADRA1BPTPN1PTPN6 | |
| SCHEMBL314791 | 0.83 | CYP1A2 (0.39) | ADRA1DADRA1AADRA1BFYNPTPN1 | |
| SCHEMBL314792 | 0.83 | CYP1A2 (0.39) | ADRA1DADRA1AADRA1BFYNPTPN1 | |
| SCHEMBL316053 | 0.82 | ADRA1D (0.34) | ADRA1DADRA1AADRA1BPTPN1PTPN6 | |
| SCHEMBL316054 | 0.82 | ADRA1D (0.34) | ADRA1DADRA1AADRA1BPTPN1PTPN6 | |
| SCHEMBL2409841 | 0.80 | ADRA2A (0.36) | FYNADORA3 | |
| SCHEMBL2409844 | 0.80 | ADRA2A (0.36) | FYNADORA3 | |
| SCHEMBL2410075 | 0.78 | PPARD (0.33) | PTPN1PTPN6PTPN11ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | ADRA1D 4359/4885ADRA1A 4372/4885ADRA1B 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.